NCT00310518View on ClinicalTrials.gov

Safety and Efficacy Study of ARQ 501 in Adult Patients With Leiomyosarcoma

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

July 31, 2007

Study Completion Date

July 31, 2007

Conditions
Cancer
Interventions
DRUG

ARQ 501

Trial Locations (5)

10021

Memorial Sloan-Kettering Cancer Center, New York

19106

Pennsylvania Oncology Hematology Associates, Philadelphia

85260

Premiere Oncology of Arizona, Scottsdale

90404

Premiere Oncology, Santa Monica

91010

City of Hope Medical Center, Duarte

All Listed Sponsors
lead

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

INDUSTRY

NCT00310518 - Safety and Efficacy Study of ARQ 501 in Adult Patients With Leiomyosarcoma | Biotech Hunter | Biotech Hunter